Drugs / HSA-GCSF
HSA-GCSF
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT02465801 | Dec 2014 → Dec 2015 | neutropenia | Tianjin SinoBiotech Ltd. | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HSA-GCSF | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02465801 ↗ |
| Known as | recombinant human serum albumin/granulocyte colony-stimulating factor fusion protein | “Recombinant Human Serum Albumin/Granulocyte Colony-Stimulating Factor Fusion Protein（1.2mg）will be injected subcutaneously” NCT02465801 ↗ |
| Known as | rHSA/G-CSF | “BACKGROUND: To evaluate the efficacy and safety of recombinant human serum albumin /granulocyte colony-stimulating factor (rHSA/G-CSF) in breast cancer following receipt of...” PMID 33789616 ↗ Mar 2021 |
| Modality | Protein / enzyme biologic | “recombinant human serum albumin/granulocyte colony-stimulating factor fusion protein” NCT02465801 ↗ |
| Route | Subcutaneous | “will be injected subcutaneously” NCT02465801 ↗ |